CONDENSED CONSOLIDATED BALANCE SHEETS $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Current assets:
Cash and cash equivalents	$ 537	$ 537	$ 5,158
Prepaid expenses and other current assets	1,834	1,834	1,064
Total current assets	2,371	2,371	6,222
Property and equipment, net	258	258	332
Operating lease right-of-use asset	1,346	1,346	262
Other assets	29	29	29
Total assets	4,004	4,004	6,845
Current liabilities:
Accounts payable	4,630	4,630	3,388
Accrued clinical trials expenses	1,373	1,373	5,128
Accrued compensation	1,563	1,563	943
Other accrued expenses	3,160	3,160	3,590
Total current liabilities	10,726	10,726	13,049
Convertible notes at fair value, including related party amount of $13,292 and $0, at June 30, 2024 and December 31, 2023, respectively	15,170	15,170
Operating lease liability	1,204	1,204
Warrant liability	1,844	1,844	1,447
Contingent consideration liability	6,886	6,886	104,350
Embedded forward purchase agreements and derivative liabilities	264	264	41,043
Total liabilities	36,094	36,094	159,889
Commitments and contingencies
Stockholders' Deficit:
Class A common stock, $0.0001 par value; 500,000,000 shares authorized at September 30, 2024 and December 31, 2023, and 39,587,630 and 37,159,600 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	4	4	4
Additional paid-in capital	401,585	401,585	381,264
Subscription receivables			(60,710)
Accumulated deficit	(433,679)	(433,679)	(473,602)
Total stockholders' deficit	(32,090)	(32,090)	(153,044)
Total liabilities and stockholders' deficit	$ 4,004	$ 4,004	$ 6,845
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor